$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Colorectal Cancer - Pipeline Review, H1 2017 [Report Updated: 30-06-2017]

Published by Global Markets Direct: 30 Jun 2017 | 100100 | In Stock

Introduction

Colorectal Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H1 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 25, 108, 137, 10, 173, 26 and 10 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 18, 9, 28 and 5 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Colorectal Cancer - Pipeline Review, H1 2017 [Report Updated: 30-06-2017]

  • Table of Contents

    Table of Contents 2

    Introduction 11

    Colorectal Cancer - Overview 12

    Colorectal Cancer - Therapeutics Development 13

    Colorectal Cancer - Therapeutics Assessment 66

    Colorectal Cancer - Companies Involved in Therapeutics Development 94

    Colorectal Cancer - Drug Profiles 223

    Colorectal Cancer - Dormant Projects 1708

    Colorectal Cancer - Discontinued Products 1725

    Colorectal Cancer - Product Development Milestones 1730

    Appendix 1745

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

100100 | GMDHC9472IDB

Number of Pages

1799

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Colorectal Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Colorectal Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021
The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.9...
15 Sep 2016 by MarketsandMarkets USD $5,650 More Info
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Me...
06 Aug 2016 by Global Data USD $4,000 More Info
Colorectal Cancer Therapeutics Market in APAC 2015-2019
About colorectal cancerColorectal cancer refers to malignancies that originate in the rectum or the ...
16 Dec 2015 by Technavio USD $3,000 More Info
Global Colorectal Cancer Drugs Market 2015-2019
About Colorectal Cancer Colorectal cancer refers to malignancies that originate in the rectum or the...
17 Jun 2015 by Technavio USD $3,000 More Info
Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics
Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced ...
31 Jan 2015 by GBI Research USD $4,995 More Info
Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics
Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced ...
31 Jan 2015 by GBI Research USD $4,995 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info
Colorectal Cancer -- KOL Insight Module
IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift du...
01 Oct 2013 by FirstWord Pharma USD $7,900 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Colorectal Cancer - Pipeline Review, H1 2017 [Report Updated: 30-06-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data